BioNexus Gene Lab (BGLC) Net Margin (2018 - 2026)

BioNexus Gene Lab has disclosed Net Margin across 9 years of filings, most recently posting 376.14% for Q2 2026.

• In Q2 2026, Net Margin fell 34888.0% year-over-year to 376.14%; the TTM figure through Jun 2026 stood at 82.36% (down 5165.0% YoY), while the FY2025 annual figure was 40.2%, down 2339.0% from the prior year.
• Net Margin came in at 376.14% for Q2 2026 at BioNexus Gene Lab, up from 2379.72% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 15.46% in Q4 2023 to a low of 2379.72% in Q1 2026.
• Average Net Margin over 5 years is 178.9%, with a median of 12.57% recorded in 2023.
• Year-over-year, Net Margin jumped 5103 bps in 2024 and plunged 235055 bps in 2026.
• Over 5 years, Net Margin stood at 2.32% in 2022, then jumped by 567 bps to 15.46% in 2023, then sank by 189 bps to 13.8% in 2024, then sank by 1452 bps to 214.18% in 2025, then slumped by 76 bps to 376.14% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 376.14% in Q2 2026, 2379.72% in Q1 2026, and 214.18% in Q4 2025.